Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans
Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular‑RNA (circRNA) therapeutic HM2003 Injection...
RNAi / ASO
CSPC’s SYH2061 Injection Receives NMPA Clinical‑Trial Approval for IgA Nephropathy
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its independently developed Class 1 chemical novel drug...
China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into...
Youcare Pharma Secures FDA Approval for YKYY013, a Novel siRNA Therapy for Chronic Hepatitis B
Youcare Pharmaceutical Group (SHA: 688658) announced that the U.S. Food and Drug Administration (FDA) has...
Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex DRx Implant Development
Biogen Inc. (NASDAQ: BIIB) announced the acquisition of Massachusetts‑based Alcyone Therapeutics. The deal centers on...
Jiangsu Hengrui HRS‑5635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis B
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next‑generation small‑interfering RNA...
Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1 B in Cardio siRNA Deal
Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund 3, L.P. to form Kalexo...
Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application
Shanghai‑based Rona Therapeutics Inc. announced on September 15, 2025 that it has formally submitted a Clinical Trial...
Sirnaomics Secures HK$138 M Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines
Sirnaomics Ltd. (HKG: 2257) announced a strategic investment agreement with Bloomage Biotech (Hong Kong) Limited, a...
Argo Biopharma, Novartis Expand siRNA Collaboration for Cardiovascular Drugs
Argo Biopharma, a Shanghai‑based siRNA drug developer, announced a new strategic cooperation agreement with Novartis...
Replicate Bioscience Teams With Novo Nordisk On srRNA‑Powered Metabolic Drugs
Replicate Bioscience, a pioneer in self‑replicating RNA (srRNA) therapeutics, announced a landmark multi‑year research partnership...
Arrowhead Partners with Novartis for ARO‑SNCA siRNA Therapy
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today unveiled a worldwide licensing and collaboration agreement with Novartis...
ChemPartner & Hayoo Forge Nucleic‑Acid Delivery Partnership to Expand Extranodal Therapies
Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149) and Hayoo Biotech have...
Regeneron’s Cemdisiran Beats Key Milestones in Phase III gMG Trial
US-based Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Aug 27, 2025 disclosed that its investigational monotherapy, cemdisiran,...
Ionis Pharmaceuticals’ DAWNZERA Approved by FDA for HAE Prevention
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced on August 22, 2025, that the U.S. Food and...
Vivatides Therapeutics Completes Multi-Million Dollar Seed Financing to Advance Nucleic Acid Delivery Platform
Biopharmaceutical company Vivatides Therapeutics has successfully completed a multi-million dollar seed round financing led by...
Skyhawk Therapeutics Collaborates with Merck on RNA-Targeting Small Molecules for Neurological Diseases
Skyhawk Therapeutics, Inc. announced on August 18, 2025, a strategic research collaboration with Merck KGaA...
Novartis’ Leqvio Approved by FDA as Standalone Therapy for Hypercholesterolemia
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 12, 2025, that the U.S. Food...
AusperBio Gains NMPA Approval for Phase III Trials of AHB-137 in Chronic Hepatitis B
Sino-US liver therapy developer AusperBio announced that the National Medical Products Administration (NMPA) has approved...
AusperBio Secures $50M in Oversubscribed Series B+ Round to Advance Hepatitis B Therapy
Sino-US liver therapy developer AusperBio announced the successful closing of an oversubscribed Series B+ financing...